CA2692970A1 - Biomarqueurs pour le diabete, l'obesite, et/ou l'hypertension - Google Patents

Biomarqueurs pour le diabete, l'obesite, et/ou l'hypertension Download PDF

Info

Publication number
CA2692970A1
CA2692970A1 CA 2692970 CA2692970A CA2692970A1 CA 2692970 A1 CA2692970 A1 CA 2692970A1 CA 2692970 CA2692970 CA 2692970 CA 2692970 A CA2692970 A CA 2692970A CA 2692970 A1 CA2692970 A1 CA 2692970A1
Authority
CA
Canada
Prior art keywords
test
control
sample
fraction
depleted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2692970
Other languages
English (en)
Inventor
William S. Hancock
Marina Hincapie
M.K. Disni R. Dayarathna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Northeastern University Boston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeastern University Boston filed Critical Northeastern University Boston
Publication of CA2692970A1 publication Critical patent/CA2692970A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/321—Arterial hypertension
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/322—Orthostatic hypertension or syncope
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA 2692970 2007-07-03 2008-07-03 Biomarqueurs pour le diabete, l'obesite, et/ou l'hypertension Abandoned CA2692970A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95812507P 2007-07-03 2007-07-03
US60/958,125 2007-07-03
PCT/US2008/069145 WO2009006568A1 (fr) 2007-07-03 2008-07-03 Biomarqueurs pour le diabète, l'obésité, et/ou l'hypertension

Publications (1)

Publication Number Publication Date
CA2692970A1 true CA2692970A1 (fr) 2009-01-08

Family

ID=40226539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2692970 Abandoned CA2692970A1 (fr) 2007-07-03 2008-07-03 Biomarqueurs pour le diabete, l'obesite, et/ou l'hypertension

Country Status (4)

Country Link
US (1) US8628912B2 (fr)
EP (1) EP2174134B1 (fr)
CA (1) CA2692970A1 (fr)
WO (1) WO2009006568A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2265949A4 (fr) * 2008-03-28 2013-02-20 Univ Ohio Isoformes de protéine pour diagnostic
WO2011005717A1 (fr) * 2009-07-07 2011-01-13 Intrinsic Bioprobes, Inc. Rapport phénotypique d'amyloïde sérique dans le prédiabète et le diabète de type 2
CN103376324A (zh) * 2012-04-25 2013-10-30 中国科学院上海生命科学研究院 白蛋白作为肥胖型糖尿病标志物的应用
EP3109630B1 (fr) * 2014-02-18 2020-02-12 Shimadzu Corporation Procédé de détection de protéine au moyen de la spectrométrie de masse
RU2021107639A (ru) * 2015-02-27 2021-04-22 Сфинготек Гмбх Способ прогнозирования риска развития ожирения у субъекта
WO2018136825A1 (fr) * 2017-01-19 2018-07-26 Cedars-Sinai Medical Center Procédés à base de spectrométrie de masse et hautement multiplexés permettant de mesurer 72 protéines humaines
CN108845142A (zh) * 2018-06-19 2018-11-20 上海伦泽生物科技有限公司 Emc10蛋白检测物在制备肥胖症诊断和程度评估以及肥胖治疗效果评价产品中的应用
CN111650372A (zh) * 2019-03-04 2020-09-11 中国医学科学院药物研究所 载脂蛋白c1在作为胃癌诊断及预后评价生物标记物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2093569A3 (fr) * 2004-05-21 2009-11-11 The Institute for Systems Biology Compositions et procédés pour la quantification de glycoprotéines sériques
US7449116B2 (en) * 2004-10-01 2008-11-11 Agilent Technologies, Inc. Methods and systems for protein separation
EP1949105A4 (fr) * 2005-10-11 2009-06-17 Tethys Bioscience Inc Marqueurs associés au diabète et procédés d'utilisation de ceux-ci
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease

Also Published As

Publication number Publication date
EP2174134A1 (fr) 2010-04-14
US20110097757A1 (en) 2011-04-28
EP2174134B1 (fr) 2013-10-09
EP2174134A4 (fr) 2011-04-20
US8628912B2 (en) 2014-01-14
WO2009006568A1 (fr) 2009-01-08

Similar Documents

Publication Publication Date Title
Dayarathna et al. A two step fractionation approach for plasma proteomics using immunodepletion of abundant proteins and multi‐lectin affinity chromatography: Application to the analysis of obesity, diabetes, and hypertension diseases
US8628912B2 (en) Biomarkers for diabetes, obesity, and/or hypertension
Yanagisawa et al. Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients
Frolov et al. Glycation sites of human plasma proteins are affected to different extents by hyperglycemic conditions in type 2 diabetes mellitus
EP2310861B1 (fr) Biomarqueurs pour rein sain
US20050272095A1 (en) Methods of identifying biomarkers
Riaz et al. Proteomic identification of human urinary biomarkers in diabetes mellitus type 2
Riaz et al. Effect of high dose thiamine on the levels of urinary protein biomarkers in diabetes mellitus type 2
JP2012524883A (ja) 腎臓障害生物マーカとしてのｗｎｔ１
Bellei et al. Proteomic analysis of early urinary biomarkers of renal changes in type 2 diabetic patients
Patel et al. Characterization of low molecular weight urinary proteins at varying time intervals in type 2 diabetes mellitus and diabetic nephropathy patients
TWI822802B (zh) 腎病變蛋白生物標記及其應用
KR100882471B1 (ko) 당뇨병성 신증 진단용 바이오 마커 조성물
US20200292558A1 (en) Prognosis and progression biomarkers for chronic kidney disease
EP3132269B1 (fr) Diagnostic d'une néphropathie chronique par analyse quantitative de modifications post-translationnelles des protéines plasmatiques
Kunika et al. Damage of charge-dependent renal tubular reabsorption causes diabetic microproteinuria
Paulo et al. Sample handling of body fluids for proteomics
Ozdemir et al. An evaluation of both serum Klotho/FGF-23 and apelin-13 for detection of diabetic nephropathy
KR102475926B1 (ko) 전신 홍반성 루푸스 진단용 바이오마커 조성물 및 이를 이용한 전신 홍반성 루푸스 진단에 필요한 정보를 제공하는 방법
CN111487338B (zh) 一种与肾功能相关的无创生物标记物及其应用
Li et al. Simultaneous quantification of apolipoproteins AI, E, and J in human plasma by LC-MS/MS for clinical application to diabetes mellitus complicated with cardiovascular disease
Mötzing et al. Immunological Quantitation of the Glycation Site Lysine‐414 in Serum Albumin in Human Plasma Samples by Indirect ELISA Using Highly Specific Monoclonal Antibodies
Delrue The use of proteomics in diabetic nephropathy
Haigh et al. Development of a novel polyclonal antibody-based immunoassay for the quantitation of non-albumin urinary proteins
Cassiday Candidate biomarkers for type 1 diabetes

Legal Events

Date Code Title Description
FZDE Dead